logo

Acadia Pharmaceuticals Inc (ACAD)



Trade ACAD now with
  Date
  Headline
9/12/2022 7:41:07 AM Acadia Pharma:FDA Accepts Filing Of Trofinetide NDA For Rett Syndrome
7/18/2022 4:11:31 PM Acadia Pharma Submits New Drug Application To U.S. FDA For Trofinetide For Treatment Of Rett Syndrome
6/17/2022 7:07:11 AM Acadia Pharma Stock Trading Halted Today
2/16/2022 9:08:35 AM Acadia Announces Resubmission Of SNDA To U.S. FDA For NUPLAZID To Treat Alzheimer's Disease Psychosis
1/10/2022 7:10:58 AM Acadia, Stoke Therapeutics To Pursue Multiple RNA-based Treatments For Severe &Rare Genetic Neurodevelopmental Diseases
12/20/2021 4:10:16 PM Acadia Pharma Announces Plan For Resubmission Of SNDA To FDA For NUPLAZID (pimavanserin)
12/14/2021 9:31:08 AM Acadia Pharma Announces Promotion Of Mark Schneyer To EVP, CFO
11/2/2021 9:11:33 AM Acadia Pharma Presents New Dementia-Related Psychosis Real-World Outcomes Data
10/25/2021 9:08:37 AM Acadia To Present Data On Pimavanserin In Patients With Parkinson's Disease Dementia With Psychosis From HARMONY Trial
7/21/2021 5:11:12 PM New England Journal Of Medicine Publishes Results From Phase 3 Study Of Pimavanserin In Dementia-Related Psychosis
6/3/2021 9:11:07 AM Acadia Says NUPLAZID Efficacy Data From OLE Study Published In Parkinsonism And Related Disorders
4/5/2021 6:41:04 AM Acadia Receives CRL From FDA For SNDA For Pimavanserin For Treatment Of Hallucinations And Delusions Associated With DRP
7/26/2012 7:45:11 AM Acadia Pharma: What's Next?